Topic 103

respiratory coronavirus syndrome acute severe sars cov covid 19 pandemic 2019 virus viral coronaviruses microbiology spike caused disease agent infectious spread viruses vaccine outbreak causative host vaccines infection health worldwide infected global public china nucleocapsid replication wuhan entry rna protein vero transmission antiviral structural world mers ongoing 2020 december covs proteins plaque has enveloped effective antibodies human e6 against humans cryo drug inactivation its ncov crisis novel infectivity newly development nonstructural drugs susceptible reported effectively recombinant rapidly available currently zoonotic pathogenic current insights million emerged particles structure report urgently coronaviridae infections 000 em furin trimer domain glycoprotein like will biosafety

135 items. Top items listed below.

Many bat species are not potential hosts of SARS-CoV and SARS-CoV-2: Evidence from ACE2 receptor usage 36 1

Susceptibility of ferrets, cats, dogs, and different domestic animals to SARS-coronavirus-2 103 1

Monoclonal antibodies for the S2 subunit of spike of SARS-CoV cross-react with the newly-emerged SARS-CoV-2 36 1

Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza 103 1

Shotgun proteomics of SARS-CoV-2 infected cells and its application to the optimisation of whole viral particle antigen production for vaccines 103 1

Alpha-1 antitrypsin inhibits SARS-CoV-2 infection 103 73 1

SARS-CoV-2 Isolation and Propagation from Turkish COVID-19 patients 103 1

SARS-CoV-2 mutations and where to find them: An in silico perspective of structural changes and antigenicity of the Spike protein 103 1

CD8+ T cell cross-reactivity against SARS-CoV-2 conferred by other coronavirus strains and influenza virus 191 76 1

Synthetic antibodies neutralize SARS-CoV-2 infection of mammalian cells 103 36 1

Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies 76 1

When Darkness Becomes a Ray of Light in the Dark Times: Understanding the COVID-19 via the Comparative Analysis of the Dark Proteomes of SARS-CoV-2, Human SARS and Bat SARS-Like Coronaviruses 103 1

The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection 36 1

A mobile genetic element in the SARS-CoV-2 genome is shared with multiple insect species 103 1

Distinct Structural Flexibility within SARS-CoV-2 Spike Protein Reveals Potential Therapeutic Targets 103 1

Insights on cross-species transmission of SARS-CoV-2 from structural modeling 103 1

Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for COVID-19 36 1

Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement 36 24 1

SARS-CoV-2 neutralizing serum antibodies in cats: a serological investigation 130 103 1

Characterization of the SARS-CoV-2 Spike in an Early Prefusion Conformation 103 1

Impact of Thiol-Disulfide Balance on the Binding of Covid-19 Spike Protein with Angiotensin Converting Enzyme 2 Receptor 36 1

Potent Antiviral Activities of Type I Interferons to SARS-CoV-2 Infection 103 44 1

Establishment of an African green monkey model for COVID-19 103 73 1

SARS-CoV-2 Nucleocapsid protein is decorated with multiple N- and O-glycans. 103 1

The crystal structure of nsp10-nsp16 heterodimer from SARS CoV-2 in complex with S-adenosylmethionine 103 1

Rescue of SARS-CoV-2 from a single bacterial artificial chromosome 103 44 1

Genomic Mutations and Changes in Protein Secondary Structure and Solvent Accessibility of SARS-CoV-2 (COVID-19 Virus) 103 37 1

Whole genome identification of potential G-quadruplexes and analysis of the G-quadruplex binding domain for SARS-CoV-2 103 1

Comparative analyses of SAR-CoV2 genomes from different geographical locations and other coronavirus family genomes reveals unique features potentially consequential to host-virus interaction and pathogenesis 103 1

Which animals are at risk? Predicting species susceptibility to Covid-19 36 1

Potent mouse monoclonal antibodies that block SARS-CoV-2 infection 103 1

Establishment of a reverse genetics system for SARS-CoV-2 using circular polymerase extension reaction 103 1

Generation of tonsil organoids as an ex vivo model for SARS-CoV-2 infection 103 73 44 1

An ultrasensitive, rapid, and portable coronavirus SARS-CoV-2 sequence detection method based on CRISPR-Cas12 103 35 1

Development of a high-throughput homogeneous AlphaLISA drug screening assay for the detection of SARS-CoV-2 Nucleocapsid 103 44 1

Increasing Host Cellular Receptor--Angiotensin-Converting Enzyme 2 (ACE2) Expression by Coronavirus may Facilitate 2019-nCoV Infection 36 1

Mapping the Immunodominance Landscape of SARS-CoV-2 Spike Protein for the Design of Vaccines against COVID-19 24 1

SARS-CoV-2 manipulates the SR-B1-mediated HDL uptake pathway for its entry 36 1

Multivariate Analyses of Codon Usage of SARS-CoV-2 and other betacoronaviruses 103 37 1

Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2 103 1

The landscape of SARS-CoV-2 RNA modifications 103 1

Functional and Genetic Analysis of Viral Receptor ACE2 Orthologs Reveals a Broad Potential Host Range of SARS-CoV-2 36 1

Potential host range of multiple SARS-like coronaviruses and an improved ACE2-Fc variant that is potent against both SARS-CoV-2 and SARS-CoV-1 36 1

Divergent SARS-CoV-2-specific T and B cell responses in severe but not mild COVID-19 73 1

Structural basis of RNA recognition by the SARS-CoV-2 nucleocapsid phosphoprotein 103 1

Computational analysis on the ACE2-derived peptides for neutralizing the ACE2 binding to the spike protein of SARS-CoV-2 36 1

SARS-CoV-2 invades host cells via a novel route: CD147-spike protein 103 1

The immunodominant and neutralization linear epitopes for SARS-CoV-2 24 1

Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies 36 24 1

Genetic analysis of the novel SARS-CoV-2 host receptor TMPRSS2 in different populations. 36 1

Propagation, inactivation, and safety testing of SARS-CoV-2 103 1

Re-analysis of SARS-CoV-2 infected host cell proteomics time-course data by impact pathway analysis and network analysis. A potential link with inflammatory response. 73 1

De novo design of ACE2 protein decoys to neutralize SARS-CoV-2 36 1

SARS-CoV-2 detection with CRISPR diagnostics 103 35 1

Isolation and characterization of SARS-CoV-2 from the first US COVID-19 patient 103 1

Interaction of human ACE2 to membrane-bound SARS-CoV-1 and SARS-CoV-2 S glycoproteins 36 1

Nucleocapsid protein of SARS-CoV-2 phase separates into RNA-rich polymerase-containing condensates 103 1

A Small interfering RNA lead targeting RNA-dependent RNA-polymerase effectively inhibit the SARS-CoV-2 infection in Golden Syrian hamster and Rhesus macaque 103 73 1

Cryo-electron microscopy structure of the SADS-CoV spike glycoprotein provides insights into an evolution of unique coronavirus spike proteins 103 1

Identification of conserved epitopes in SARS-CoV-2 spike and nucleocapsid protein. 103 1

The effect of whey protein on viral infection and replication of SARS-CoV-2 and pangolin coronavirus in vitro 103 1

Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 Infection 36 1

Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. 44 1

Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies. 36 1

Designed peptides as potential fusion inhibitors against SARA-CoV-2 coronavirus infection 103 1

SARS-CoV-2 RNA shedding in recovered COVID-19 cases and the presence of antibodies against SARS-CoV-2 in recovered COVID-19 cases and close contacts 103 1

Spike protein binding prediction with neutralizing antibodies of SARS-CoV-2 1

A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability 36 24 1

SARS-CoV-2 infection severity is linked to superior humoral immunity against the spike 24 1

SARS-CoV-2 assays to detect functional antibody responses that block ACE2 recognition in vaccinated animals and infected patients 24 1

Methyltransferase-like 3 modulates severe acute respiratory syndrome coronavirus-2 RNA N6-methyladenosine modification and replication 103 1

Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro. 44 1

Naturally mutated spike proteins of SARS-CoV-2 variants show differential levels of cell entry 36 1

Evidence of the Recombinant Origin and Ongoing Mutations in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) 37 1

Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2 44 1

Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide 73 36 1

The SARS-CoV-2 Envelope and Membrane proteins modulate maturation and retention of the Spike protein, allowing optimal formation of VLPs in presence of Nucleoprotein 103 1

SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses 24 1

Comparative transcriptome analysis reveals the intensive early-stage responses of host cells to SARS-CoV-2 infection 73 1

Machine intelligence design of 2019-nCoV drugs 103 44 1

Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay 36 1

Structural characterization of Nonstructural protein 1 from SARS-CoV-2 103 1

Elucidating the differences in the molecular mechanism of receptor binding between 2019-nCoV and the SARS-CoV viruses using computational tools 36 1

TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets 44 1

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity 44 1

Oral delivery of SARS-CoV-2 DNA vaccines using attenuated Salmonella typhimurium as a carrier in rat 103 1

Rapid, sensitive, full genome sequencing of Severe Acute Respiratory Syndrome Virus Coronavirus 2 (SARS-CoV-2) 103 37 1

SARS-CoV-2 viral budding and entry can be modeled using virus-like particles 103 1

Establishment of murine hybridoma cells producing antibodies against spike protein of SARS-CoV-2 103 1

Comparative analysis of primer-probe sets for the laboratory confirmation of SARS-CoV-2 103 37 1

Integrated characterization of SARS-CoV-2 genome, microbiome, antibiotic resistance and host response from single throat swabs 103 73 1

Insights into The Codon Usage Bias of 13 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Isolates from Different Geo-locations 103 37 1

SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery 73 1

Structural Basis of RNA Cap Modification by SARS-CoV-2 Coronavirus 103 1

A Multiscale and Comparative Model for Receptor Binding of 2019 Novel Coronavirus and the Implication of its Life Cycle in Host Cells 36 1

Oral epithelial expression of angiotensin converting enzyme-2: Implications for COVID-19 diagnosis and prognosis. 36 1

SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus 73 1

Molecular Detection of SARS-CoV-2 in Formalin Fixed Paraffin Embedded Specimens 103 1

Production of ORF8 protein from SARS-CoV-2 using an inducible virus-mediated expression-system in suspension-cultured tobacco BY-2 cells 103 1

Epitope-Based Peptide Vaccine Against Severe Acute Respiratory Syndrome-Coronavirus-2 Nucleocapsid Protein: An in silico Approach 191 76 1